Welcome To ChemAnalyst
India’s Clopidogrel prices moved sharply upward during May 2026, supported by strong institutional procurement and tightening domestic availability. Early-month Jan Aushadhi tenders accelerated bulk purchases of Clopidogrel ahead of the monsoon quarter, while hospital procurement and precautionary stocking by large healthcare chains absorbed a significant portion of available supply. Domestic Clopidogrel producers operated cautiously following recent US FDA re-inspections, prioritizing compliant batch production and limiting immediate supply growth. Meanwhile, exports of Clopidogrel weakened as buyers in Russia and Brazil shifted toward lower-priced Chinese alternatives, reducing overseas demand pressure. Rising feedstock costs for intermediates such as methyl lactate and pyridine derivatives, combined with higher coal-based electricity tariffs, further strengthened Clopidogrel production costs. Looking forward, the Clopidogrel market is expected to remain firm amid sustained domestic procurement activity and elevated manufacturing costs.
We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site or by closing this box, you consent to our use of cookies. More info.
